TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8025301

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha-2b (r-IFN-alpha-2b) 6 MU tiw for 2 months followed by 3 MU for 7 months (Group A)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha-2b (r-IFN-alpha-2b) 6 MU tiw for 2 months followed by 1.5 MU for 7 months (Group B)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Both groups (A and B) during the first two months at 6 MU
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Group A (3 MU)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Group B (1.5 MU)
Number of subjects: 117
Study: 2514653

Group type: EXPERIMENTAL
Intervention: Cicletanine 150-200 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Indapamide 2.5 mg/day
Number of subjects: 31
Study: 4393354

Group type: EXPERIMENTAL
Intervention: Propranolol (5 to 1,280 mg orally)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sotalol (5 to 1,280 mg orally)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control period (no drug)
Number of subjects: 16
Study: 30554237

Group type: EXPERIMENTAL
Intervention: Educational intervention on influenza infection and vaccination (38 participants)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (87 participants)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both groups (125 participants)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Healthcare Workers who underwent vaccination
Number of subjects: 125
Study: 29096156

Group type: EXPERIMENTAL
Intervention: Obese patients with ER-negative breast cancer
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Obese patients with premenopausal ER-positive tumours
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Overweight patients with premenopausal ER-positive tumours
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Overweight patients with postmenopausal ER-positive tumours
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Obese patients with postmenopausal ER-positive tumours
Number of subjects: 734
Study: 25427411

Group type: EXPERIMENTAL
Intervention: Dor fundoplication
Number of subjects: 62

Group type: COMPARATOR
Intervention: Angle of His accentuation
Number of subjects: 62
Study: 23253647

Group type: EXPERIMENTAL
Intervention: Screening and care strategy
Number of subjects: 3538

Group type: COMPARATOR
Intervention: Education and environment strategies
Number of subjects: 3538
Study: 21981909

Group type: EXPERIMENTAL
Intervention: Patient Self-Management Support intervention (12 sessions, starting prior to surgery and continuing for approximately 9 weeks post-TKR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 0
Study: 18306243

Group type: EXPERIMENTAL
Intervention: Istradefylline (40mg/day)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 14756610

Group type: EXPERIMENTAL
Intervention: Cognitive trauma therapy for battered women with PTSD (CTT-BW)
Number of subjects: 125
Study: 11177402

Group type: EXPERIMENTAL
Intervention: Zidovudine and didanosine (dual therapy)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Zidovudine, didanosine, and lamivudine (triple therapy)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 137
Study: 9638980

Group type: EXPERIMENTAL
Intervention: Normal-risk group receiving CHOP chemotherapy
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: High-risk patients treated with low-dose CHOP
Number of subjects: 158

Group type: COMPARATOR
Intervention: High-risk patients treated with vincristine/prednisone
Number of subjects: 158

Group type: COMPARATOR
Intervention: Normal-risk patients during chemotherapy
Number of subjects: 158
Study: 8091999

Group type: EXPERIMENTAL
Intervention: Depot antipsychotic medication during the initial 1-year period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication-free period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance antipsychotic medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low expressed emotion environment
Number of subjects: 0
Study: 2734719

Group type: EXPERIMENTAL
Intervention: Antacid treatment (Rocgel)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29727048

Group type: EXPERIMENTAL
Intervention: Laser photobiomodulation (PBM)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 101
Study: 26424178

Group type: EXPERIMENTAL
Intervention: TAVI-GA (General Anaesthesia)
Number of subjects: 66

Group type: COMPARATOR
Intervention: TAVI-S (Sedation)
Number of subjects: 66
Study: 24206823

Group type: EXPERIMENTAL
Intervention: Buttermilk (45 g/d)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (45 g/d)
Number of subjects: 34
Study: 22309805

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endothelin-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor + Endothelin-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20668532

Group type: EXPERIMENTAL
Intervention: Positive mood-high arousal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative mood-low arousal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive mood-low arousal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative mood-high arousal
Number of subjects: 0
Study: 18538464

Group type: EXPERIMENTAL
Intervention: Thrombotripsy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 16001993

Group type: EXPERIMENTAL
Intervention: PLD 50 mg/m2 I.V. on day 1 and cyclophosphamide 100 mg/m2 orally on days 1‐14 every 28‐day cycle
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: PLD 30 mg/m2 plus cyclophosphamide 600 mg/m2 I.V. on day 1 every 21 days
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: PLD 35 mg/m2 plus cyclophosphamide 600 mg/m2 I.V. on day 1 every 21 days
Number of subjects: 51
Study: 11346839

Group type: EXPERIMENTAL
Intervention: Vignette case history of an amputation patient varying in age (36yr, 76yr), gender (male, female), and behavior (ideal, depressed, noncompliant) followed by the Professional Bias Questionnaire (PBQ).
Number of subjects: 974

Group type: EXPERIMENTAL
Intervention: Professional Bias Questionnaire (PBQ) assessing responses to the vignette.
Number of subjects: 974
Study: 9580385

Group type: EXPERIMENTAL
Intervention: CVP + IFN (3 MU/m2 three times a week for 3 months)
Number of subjects: 155

Group type: COMPARATOR
Intervention: CVP alone
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: CVP + IFN
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Maintenance IFN
Number of subjects: 155
Study: 8040634

Group type: EXPERIMENTAL
Intervention: Intervention with prominent dialogue, social interactions, and scaffolded instruction
Number of subjects: 109

Group type: COMPARATOR
Intervention: Other intervention (not specified)
Number of subjects: 109
Study: 3050905

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg preoperatively
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ACC-30 preoperatively
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flurbiprofen postoperatively
Number of subjects: 40

Group type: COMPARATOR
Intervention: ACC-30 postoperatively
Number of subjects: 40
Study: 31393082

Group type: EXPERIMENTAL
Intervention: Phospho-histone H2AX (γH2AX) levels
Number of subjects: 60
Study: 29120838

Group type: EXPERIMENTAL
Intervention: Urine HPV testing
Number of subjects: 217

Group type: COMPARATOR
Intervention: Pap smear
Number of subjects: 217
Study: 25782644

Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram daily from preanesthesia to postoperative day 6
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo daily from preanesthesia to postoperative day 6
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 120
Study: 23407221

Group type: EXPERIMENTAL
Intervention: 3 months of isoniazid plus rifampicin (3RH)
Number of subjects: 590

Group type: COMPARATOR
Intervention: 6 months of isoniazid (6H)
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Both 3RH and 6H
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: 3RH
Number of subjects: 590

Group type: COMPARATOR
Intervention: 6H
Number of subjects: 590
Study: 21087452

Group type: EXPERIMENTAL
Intervention: Vienna nomogram (group A)
Number of subjects: 303

Group type: COMPARATOR
Intervention: 8-core prostate biopsy (group B)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 303
Study: 19531592

Group type: EXPERIMENTAL
Intervention: PPAR alpha agonist (20 microg/d GW590735)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PPAR delta agonist (10 mg/d GW501516)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ketogenic diet
Number of subjects: 31

Group type: COMPARATOR
Intervention: PPAR gamma agonist (rosiglitazone)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fasting and refeeding
Number of subjects: 31
Study: 17569044

Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRL) 20 mg m(‐2) i.v. on day 1, Docetaxel (DCT) 60 mg m(‐2) on day 1, Oral VRL 60 mg m(‐2) on day 15 every 3 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRL) 20 mg m(‐2) i.v. with Docetaxel (DCT) 60 mg m(‐2) on day 1, Oral VRL 60 mg m(‐2) on day 15 every 3 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study: 15104197

Group type: EXPERIMENTAL
Intervention: Cutaneous allergy tests
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Histopathologic and immunohistochemical studies
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Immunoblot analysis
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IgE recognition of flea proteins
Number of subjects: 45
Study: 11208496

Group type: EXPERIMENTAL
Intervention: Drug I (propafenone, sotalol, or disopyramide)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Drug II (second antiarrhythmic drug)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Amiodarone (Drug III)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Amiodarone (after first unsuccessful CV)
Number of subjects: 58
Study: 9563814

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 12
Study: 8172365

Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30369161

Group type: EXPERIMENTAL
Intervention: Ningmitai capsules (4 capsules per time, 3 times per day)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Control group (antibiotics or sodium diclofenac suppository on demand)
Number of subjects: 269
Study: 27898683

Group type: EXPERIMENTAL
Intervention: 30-day NIAAA hazardous drinking
Number of subjects: 700

Group type: COMPARATOR
Intervention: No drinking
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Moderate drinking
Number of subjects: 700

Group type: COMPARATOR
Intervention: Injection drug use, polysubstance use, environmental risk exposures (past incarceration, police involvement, selling sex, HIV stigma)
Number of subjects: 700
Study: 24804483

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclical alendronate
Number of subjects: 0
Study: 22421008

Group type: EXPERIMENTAL
Intervention: 6-month therapy group
Number of subjects: 156

Group type: COMPARATOR
Intervention: 12-month therapy group
Number of subjects: 156
Study: 20167686

Group type: EXPERIMENTAL
Intervention: Acute water loading
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Chronic water loading
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Increased water intake of 3 L per day
Number of subjects: 23
Study: 19074351

Group type: EXPERIMENTAL
Intervention: Modafinil administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 17190281

Group type: EXPERIMENTAL
Intervention: Anal dilators
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical nitroderivatives
Number of subjects: 40
Study: 12881373

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control arm (no mammography screening)
Number of subjects: 5
Study: 11203857

Group type: EXPERIMENTAL
Intervention: IPS Empress inlays and onlays
Number of subjects: 34
Study: 8626044

Group type: EXPERIMENTAL
Intervention: Glycine-extended gastrin-17 infusion at three consecutive dose rates
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glycine-extended gastrin-17 infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glycine-extended gastrin-17 infusion during constant-rate infusion after a protein meal
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glycine-extended gastrin-17
Number of subjects: 8
Study: 1575169

Group type: EXPERIMENTAL
Intervention: Quinapril, 20 mg, administered in the evening (10 PM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Quinapril, 20 mg, administered in the morning (8 AM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3918178

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 50 mg daily for 6 to 9 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 101
Study: 30614649

Group type: EXPERIMENTAL
Intervention: 1000 mg of methylprednisolone
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 29872803

Group type: EXPERIMENTAL
Intervention: 3 g high MW (HMW) barley beta-glucan
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5 g low MW (LMW) barley beta-glucan
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 g LMW barley beta-glucan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 30
Study: 27048871

Group type: COMPARATOR
Intervention: Dry nasal low-flow oxygen (dry-NLFO)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Humidified nasal low-flow oxygen (humidified-NLFO)
Number of subjects: 18
Study: 25254489

Group type: EXPERIMENTAL
Intervention: High dose of N-acetylcysteine (NAC) and saline
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) and saline
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Both treatments (NAC and NaHCO3) and saline
Number of subjects: 500

Group type: COMPARATOR
Intervention: Saline only
Number of subjects: 500
Study: 21717449

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily
Number of subjects: 103

Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Exemestane after crossover
Number of subjects: 103

Group type: COMPARATOR
Intervention: Anastrozole after crossover
Number of subjects: 103
Study: 19521657

Group type: EXPERIMENTAL
Intervention: Unipedal standing exercise (6-month program: standing on a single foot for 1 min per leg, 3 times per day)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Unipedal standing exercise (in participants aged >/=70 years, n = 20)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no exercise, n = 11)
Number of subjects: 94
Study: 17579345

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision with preoperative radiotherapy (PRT)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Total mesorectal excision without preoperative radiotherapy (PRT)
Number of subjects: 399
Study: 16318132

Group type: EXPERIMENTAL
Intervention: Double moxibustion at Yifeng (TE 17) combined with electroacupuncture
Number of subjects: 87

Group type: COMPARATOR
Intervention: Simple electroacupuncture
Number of subjects: 87
Study: 12197847

Group type: EXPERIMENTAL
Intervention: Triple‐plus‐yogurt group (AB‐Yogurt)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Triple‐only group
Number of subjects: 160
Study: 9798043

Group type: EXPERIMENTAL
Intervention: Penicillin therapy (intramuscular benzylpenicillin, 50,000 U/[kg.d] for 5 days and then oral penicillin, 50 mg/[kg.d] for 5 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Erythromycin therapy (50 mg/[kg.d] orally for 10 days)
Number of subjects: 44
Study: 7719245

Group type: EXPERIMENTAL
Intervention: all‐trans retinoic acid (ATRA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATRA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PML‐RAR alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATRA treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PML‐RAR alpha and PLZF‐RAR alpha
Number of subjects: 0
Study: 2673129

Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nortriptyline hydrochloride
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 103469

Group type: EXPERIMENTAL
Intervention: HC 20-511 (Ketotifen)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: clemastine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: DSCG
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Number of subjects: 14
Study: 31812999

Group type: EXPERIMENTAL
Intervention: Stress scripts
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Trauma scripts
Number of subjects: 28

Group type: COMPARATOR
Intervention: Neutral scripts
Number of subjects: 28
Study: 29969577

Group type: EXPERIMENTAL
Intervention: Partial-body cryostimulation (PBC): 3 min at ‐160 °C
Number of subjects: 9

Group type: COMPARATOR
Intervention: Passive recovery at 21 °C
Number of subjects: 9
Study: 28107336

Group type: EXPERIMENTAL
Intervention: Self-affirmations
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Self-affirmations and nature sounds
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nature sounds
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study: 25629739

Group type: EXPERIMENTAL
Intervention: Less-tight control (target diastolic blood pressure, 100 mm Hg)
Number of subjects: 987

Group type: COMPARATOR
Intervention: Tight control (target diastolic blood pressure, 85 mm Hg)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Less-tight control
Number of subjects: 987

Group type: COMPARATOR
Intervention: Tight control
Number of subjects: 987
Study: 22899580

Group type: EXPERIMENTAL
Intervention: High CLLU1 expression
Number of subjects: 515

Group type: COMPARATOR
Intervention: Low CLLU1 expression
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: High CLLU1 expression among patients with mutated IGHV genes
Number of subjects: 515

Group type: COMPARATOR
Intervention: Low CLLU1 expression among patients with mutated IGHV genes
Number of subjects: 515
Study: 20496177

Group type: EXPERIMENTAL
Intervention: BAK-PLO (baclofen 10 mg, amitriptyline HCL 40 mg, ketamine 20 mg in pluronic lecithin organogel)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo (PLO)
Number of subjects: 208
Study: 19807931

Group type: EXPERIMENTAL
Intervention: Vaginal subcutaneous injection of rhFSH (Puregon 300)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Abdominal subcutaneous injection of rhFSH (Puregon 300)
Number of subjects: 12
Study: 16396729

Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation
Number of subjects: 70
Study: 12641809

Group type: EXPERIMENTAL
Intervention: Informational support about postnatal depression
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no informational support)
Number of subjects: 70
Study: 11032098

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg BID
Number of subjects: 0
Study: 9545890

Group type: EXPERIMENTAL
Intervention: Dyract/PSA
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Dyract/P&B 2.0
Number of subjects: 4

Group type: COMPARATOR
Intervention: Prisma TPH/UB3
Number of subjects: 4

Group type: COMPARATOR
Intervention: Prisma TPH/ProBond
Number of subjects: 4
Study: 8465834

Group type: EXPERIMENTAL
Intervention: MRFIT hypertensive patients with diuretic-based pharmacologic regimen
Number of subjects: 5524

Group type: EXPERIMENTAL
Intervention: Average on-treatment DBP < 95 mm Hg in MRFIT
Number of subjects: 5524

Group type: COMPARATOR
Intervention: Baseline and 1-year change in creatinine level in TOMHS
Number of subjects: 5524

Group type: COMPARATOR
Intervention: MRFIT screenees
Number of subjects: 5524

Group type: EXPERIMENTAL
Intervention: 6-year change in creatinine in MRFIT hypertensive patients
Number of subjects: 5524
Study: 3941301

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no hypnotherapy)
Number of subjects: 100
Study: 30171785

Group type: EXPERIMENTAL
Intervention: First-grade schooling group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: WM training group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: IC training group
Number of subjects: 91

Group type: COMPARATOR
Intervention: Business-as-usual kindergarten control group
Number of subjects: 91
Study: 28441094

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Number of subjects: 63225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63225
Study: 26220816

Group type: EXPERIMENTAL
Intervention: Short messaging service text
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Personal digital assistant (e.g., iPod Touch)
Number of subjects: 20
Study: 23017329

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg/45 kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 21307764

Group type: EXPERIMENTAL
Intervention: Peristaltic pneumatic compression
Number of subjects: 70
Study: 19277473

Group type: EXPERIMENTAL
Intervention: New surgical methods and procedures tested in surgical RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical RCTs conducted in six surgical trial centers
Number of subjects: 0
Study: 17140874

Group type: EXPERIMENTAL
Intervention: Mental practice and CIMT
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: CIMT
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: CIMT plus mental practice
Number of subjects: 4

Group type: COMPARATOR
Intervention: Mental practice alone
Number of subjects: 4
Study: 12771298

Group type: EXPERIMENTAL
Intervention: Calcijex injected directly into the PTG (2 microg/ml preparation)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Calcijex injected directly into the PTG (1 microg/ml preparation)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PCIT (both groups)
Number of subjects: 19